Please use this identifier to cite or link to this item:
Title: A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)
Authors: Lee, Y.-M. 
Sutedja, D.S.
Wai, C.-T. 
Dan, Y.-Y. 
Aung, M.-O. 
Zhou, L. 
Cheng, C.-L.
Wee, A.
Lim, S.-G. 
Keywords: Non-alcoholic steatohepatitis
Randomized controlled study
Issue Date: Jun-2008
Citation: Lee, Y.-M., Sutedja, D.S., Wai, C.-T., Dan, Y.-Y., Aung, M.-O., Zhou, L., Cheng, C.-L., Wee, A., Lim, S.-G. (2008-06). A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology International 2 (2) : 196-201. ScholarBank@NUS Repository.
Abstract: Purpose: Tumor necrosis factor-α (TNF-α) is implicated in non-alcoholic steatohepatitis (NASH). Pentoxifylline inhibits TNF-α. We wanted to evaluate the efficacy of Pentoxifylline on NASH patients. Methods: Patients with biopsy proven NASH and persistently elevated alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal were randomized to 3 months of treatment with a step 1 American Heart Association diet and daily exercise with Pentoxifylline or placebo. Liver function tests, serum lipids and TNF-α, Interleukin 6 (IL-6), and plasma hyaluronic acid were measured at baseline, at weeks 6 and 12. Categorical data were analyzed by Fisher's exact test while independent sample t-test and Mann-Whitney test were used for continuous data. Results: Eleven patients were randomized into the Pentoxifylline and nine to the placebo group. After 3 months of treatment body mass index (BMI), ALT and aspartate aminotransferase (AST) decreased significantly in both groups. There was no difference between the two groups in reduction of BMI (P = 0.897). There was significantly greater reduction in AST in the Pentoxifylline group (P = 0.038). There was a trend toward lower ALT level (P = 0.065) in the Pentoxifylline group. TNF-α and IL-6 decreased significantly in both groups after treatment, but there was no significant difference between the two groups. Conclusion: Three months of Pentoxifylline treatment in combination with diet and exercise results in significantly greater reduction in AST levels in patients with NASH as compared with controls. © Asian Pacific Association for the Study of the Liver 2008.
Source Title: Hepatology International
ISSN: 19360533
DOI: 10.1007/s12072-008-9058-1
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Apr 15, 2021


checked on Apr 15, 2021

Page view(s)

checked on Apr 10, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.